We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


28 September 2015 By Robert Cyran

The pharmaceuticals company keeps fighting through chronic skepticism about its acquisitive ways and the related borrowing. Now, U.S. lawmakers’ questions about drug prices have cost Valeant $11 bln in market value. Always being on the defensive could eventually take its toll.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)